-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down to $14.59
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down to $14.59
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Rating)'s share price gapped down before the market opened on Thursday . The stock had previously closed at $14.59, but opened at $12.68. Janux Therapeutics shares last traded at $12.68, with a volume of 10 shares trading hands.
Janux Therapeutics Price Performance
The stock's fifty day simple moving average is $13.41 and its 200 day simple moving average is $13.66. The firm has a market capitalization of $525.33 million, a P/E ratio of -9.61 and a beta of 1.66.
Get Janux Therapeutics alerts:Janux Therapeutics (NASDAQ:JANX – Get Rating) last posted its earnings results on Tuesday, August 9th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.04). Janux Therapeutics had a negative net margin of 809.63% and a negative return on equity of 15.10%. The company had revenue of $2.37 million during the quarter. As a group, sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.74 EPS for the current fiscal year.
Institutional Investors Weigh In On Janux Therapeutics
Several large investors have recently added to or reduced their stakes in the stock. American International Group Inc. boosted its holdings in shares of Janux Therapeutics by 25.3% in the first quarter. American International Group Inc. now owns 8,813 shares of the company's stock worth $126,000 after buying an additional 1,782 shares during the period. Amalgamated Bank acquired a new stake in shares of Janux Therapeutics in the 1st quarter valued at $28,000. Goldman Sachs Group Inc. grew its holdings in Janux Therapeutics by 21.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 17,934 shares of the company's stock worth $257,000 after acquiring an additional 3,186 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Janux Therapeutics by 34.9% in the 1st quarter. JPMorgan Chase & Co. now owns 17,926 shares of the company's stock valued at $256,000 after purchasing an additional 4,638 shares during the period. Finally, Rhumbline Advisers raised its position in shares of Janux Therapeutics by 46.9% during the first quarter. Rhumbline Advisers now owns 16,216 shares of the company's stock worth $233,000 after purchasing an additional 5,179 shares during the period. 66.07% of the stock is owned by institutional investors and hedge funds.Janux Therapeutics Company Profile
(Get Rating)
Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
Featured Stories
- Get a free copy of the StockNews.com research report on Janux Therapeutics (JANX)
- Williams-Sonoma's High-End Consumers Are Still Spending
- Snowflake Stock Soars On Strong Results
- PENN Entertainment Stock is Reset and Ready to Rebound
- NVIDIA: A Top Choice In Bifurcated Chip Market?
- 3 Payroll Software Makers Set For Growth In 2023
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Rating)'s share price gapped down before the market opened on Thursday . The stock had previously closed at $14.59, but opened at $12.68. Janux Therapeutics shares last traded at $12.68, with a volume of 10 shares trading hands.
雅諾治療公司(納斯達克代碼：JANX-GET評級)的股價在週四開盤前大幅下跌。該股此前收於14.59美元，但開盤時為12.68美元。雅諾治療公司的股票最後報12.68美元，成交量為10股。
Janux Therapeutics Price Performance
雅諾治療公司的性價比
The stock's fifty day simple moving average is $13.41 and its 200 day simple moving average is $13.66. The firm has a market capitalization of $525.33 million, a P/E ratio of -9.61 and a beta of 1.66.
該股的50日簡單移動均線為13.41美元，200日簡單移動均線為13.66美元。該公司的市值為5.2533億美元，市盈率為-9.61，貝塔係數為1.66。
Janux Therapeutics (NASDAQ:JANX – Get Rating) last posted its earnings results on Tuesday, August 9th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.04). Janux Therapeutics had a negative net margin of 809.63% and a negative return on equity of 15.10%. The company had revenue of $2.37 million during the quarter. As a group, sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.74 EPS for the current fiscal year.
雅諾治療公司(納斯達克代碼：JANX-GET評級)上一次公佈收益業績是在8月9日星期二。該公司公佈了該季度每股收益(0.41美元)，低於分析師普遍預期的(0.37美元)和(0.04美元)。雅諾治療公司的淨利潤率為負809.63%，淨資產回報率為負15.10%。該公司本季度的收入為237萬美元。賣方分析師作為一個整體預測，Janux治療公司本財年的每股收益將達到1.74美元。
Institutional Investors Weigh In On Janux Therapeutics
機構投資者對Janux治療公司的看法
Janux Therapeutics Company Profile
Janux治療公司簡介
(Get Rating)
(獲取評級)
Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
Janux治療公司是一家生物製藥公司，開發基於專有的腫瘤激活T細胞激活器(TRACTr)平臺技術的療法，用於治療癌症患者。該公司處於臨牀前或發現階段的主要候選TRACTr產品針對前列腺特異性膜抗原、表皮生長因子受體和滋養層細胞表面抗原2。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Janux Therapeutics (JANX)
- Williams-Sonoma's High-End Consumers Are Still Spending
- Snowflake Stock Soars On Strong Results
- PENN Entertainment Stock is Reset and Ready to Rebound
- NVIDIA: A Top Choice In Bifurcated Chip Market?
- 3 Payroll Software Makers Set For Growth In 2023
- 免費獲取StockNews.com關於Janux治療公司的研究報告(Janx)
- 威廉姆斯-索諾馬的高端消費者仍在消費
- 雪花股票因業績強勁而飆升
- 賓夕法尼亞娛樂公司股票重置，準備反彈
- NVIDIA：分流芯片市場的首選？
- 3家薪資軟件製造商將在2023年實現增長
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Janux治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Janux治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧